Biocryst Pharmaceuticals Stock Performance
| BCRX Stock | USD 5.27 0.82 18.43% |
BioCryst Pharmaceuticals has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 2.96, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioCryst Pharmaceuticals will likely underperform. BioCryst Pharmaceuticals right now shows a risk of 4.34%. Please confirm BioCryst Pharmaceuticals maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if BioCryst Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in BioCryst Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, BioCryst Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 18.43 | Five Day Return 14.32 | Year To Date Return (13.18) | Ten Year Return (38.36) | All Time Return (18.92) |
1 | BioCryst Pharmaceuticals Inc Reports Growth in ORLADEYO Revenue and Projects ... | 02/26/2024 |
2 | Acquisition by Theresa Heggie of 999 shares of BioCryst Pharmaceuticals at 5.63 subject to Rule 16b-3 | 02/29/2024 |
3 | Disposition of 7525 shares by Thackray Helen M. of BioCryst Pharmaceuticals at 5.08 subject to Rule 16b-3 | 03/28/2024 |
4 | Can the Uptrend Continue for BioCryst - Yahoo Canada Shine On | 04/12/2024 |
5 | Pint Pharma anuncia a aprovao de ORLADEYO , primeira terapia oral, indicada como preveno das crises de angioedema hereditrio em adultos e pacientes peditricos c... | 04/16/2024 |
6 | BioCryst Announces Approval of ORLADEYO by the Brazilian Health Regulatory Agency | 04/17/2024 |
7 | BioCryst to Report First Quarter 2024 Financial Results on May 6 | 04/22/2024 |
8 | Acquisition by Milano Vincent of 680 shares of BioCryst Pharmaceuticals at 8.27 subject to Rule 16b-3 | 04/26/2024 |
9 | Insufficient Growth At BioCryst Pharmaceuticals, Inc. Hampers Share Price | 04/29/2024 |
10 | UPDATE 2-Bird flu testing shows more dairy products are safe, US FDA says | 05/01/2024 |
11 | Relay Therapeutics, Inc. Reports Q1 Loss, Tops Revenue Estimates | 05/02/2024 |
12 | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 05/03/2024 |
| Begin Period Cash Flow | 306.2 M |
BioCryst |
BioCryst Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 530.00 in BioCryst Pharmaceuticals on February 7, 2024 and sell it today you would lose (3.00) from holding BioCryst Pharmaceuticals or give up 0.57% of portfolio value over 90 days. BioCryst Pharmaceuticals is currently generating 0.081% in daily expected returns and assumes 4.3414% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than BioCryst, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioCryst Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioCryst Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioCryst Pharmaceuticals, and traders can use it to determine the average amount a BioCryst Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0187
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | BCRX | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.34 actual daily | 38 62% of assets are more volatile |
Expected Return
| 0.08 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average BioCryst Pharmaceuticals is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioCryst Pharmaceuticals by adding it to a well-diversified portfolio.
BioCryst Pharmaceuticals Fundamentals Growth
BioCryst Stock prices reflect investors' perceptions of the future prospects and financial health of BioCryst Pharmaceuticals, and BioCryst Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioCryst Stock performance.
| Return On Equity | -19.25 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.16) % | ||||
| Current Valuation | 1.55 B | ||||
| Shares Outstanding | 206.33 M | ||||
| Price To Earning | (7.11) X | ||||
| Price To Book | 56.59 X | ||||
| Price To Sales | 2.97 X | ||||
| Revenue | 331.41 M | ||||
| Gross Profit | 10.94 M | ||||
| EBITDA | (102.05 M) | ||||
| Net Income | (226.54 M) | ||||
| Cash And Equivalents | 417.48 M | ||||
| Cash Per Share | 2.24 X | ||||
| Total Debt | 848.71 M | ||||
| Debt To Equity | 2.40 % | ||||
| Current Ratio | 5.19 X | ||||
| Book Value Per Share | (2.21) X | ||||
| Cash Flow From Operations | (95.14 M) | ||||
| Earnings Per Share | (1.07) X | ||||
| Market Capitalization | 1.1 B | ||||
| Total Asset | 516.96 M | ||||
| Retained Earnings | (1.68 B) | ||||
| Working Capital | 345.98 M | ||||
| Current Asset | 65.99 M | ||||
| Current Liabilities | 64.45 M | ||||
About BioCryst Pharmaceuticals Performance
To evaluate BioCryst Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when BioCryst Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare BioCryst Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand BioCryst Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents BioCryst's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.7 K | 1.7 K | |
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.28) | (0.30) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | 0.50 | 0.52 |
Things to note about BioCryst Pharmaceuticals performance evaluation
Checking the ongoing alerts about BioCryst Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioCryst Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioCryst Pharmaceuticals had very high historical volatility over the last 90 days | |
| BioCryst Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 331.41 M. Net Loss for the year was (226.54 M) with profit before overhead, payroll, taxes, and interest of 10.94 M. | |
| BioCryst Pharmaceuticals currently holds about 417.48 M in cash with (95.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.24. | |
| BioCryst Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 87.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 |
- Analyzing BioCryst Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioCryst Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining BioCryst Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioCryst Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioCryst Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioCryst Pharmaceuticals' stock. These opinions can provide insight into BioCryst Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for BioCryst Stock analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 1.724 | Quarterly Revenue Growth 0.174 | Return On Assets (0.12) | Return On Equity (19.25) |
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.